← Leaderboards
Mohammed Kashani-Sabet
University Of California San Francisco
$9,875,867
Attributed
$9,875,867
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$9,875,867 · 7
By mechanism
R01$9,448,479 · 4
R03$227,250 · 1
M01$200,138 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Boris C Bastian$20,025,092
- Gordon B. Mills$27,749,983
- Nancy J Boudreau$4,862,627
- Stewart A Anderson$16,418,580
- Zena Werb$33,582,689
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaNeoplasm MetastasisLaboratoriesMetastatic MelanomaProteinsPrognostic MarkerGenesCohortMolecularBaseGene ExpressionProtein ExpressionNevusOutcome ForecastCdna ArraysMicroarray AnalysisCutaneous MelanomaValidationIn VivoSmall Hairpin RnaPlayPrognosticMediatingTumor
Grant awards (33)
Targeting BPTF in the Therapy of BRAF-mutant Melanoma$617,648
R01 · FY2021 · CA · contact PI
Targeting BPTF in the Therapy of BRAF-mutant Melanoma$617,648
R01 · FY2020 · CA · contact PI
Targeting BPTF in the Therapy of BRAF-mutant Melanoma$599,119
R01 · FY2019 · CA · contact PI
Targeting BPTF in the Therapy of BRAF-mutant Melanoma$617,524
R01 · FY2018 · CA · contact PI
Targeting BPTF in the Therapy of BRAF-mutant Melanoma$614,787
R01 · FY2017 · CA · contact PI
PHIP as a Biomarker of Triple-Negative Melanoma$424,835
R01 · FY2017 · CA · contact PI
PHIP as a Biomarker of Triple-Negative Melanoma$424,835
R01 · FY2016 · CA · contact PI
PHIP as a Biomarker of Triple-Negative Melanoma$424,835
R01 · FY2015 · CA · contact PI
Validation of Genomic Targets in Melanoma$312,281
R01 · FY2015 · CA · contact PI
PHIP as a Biomarker of Triple-Negative Melanoma$424,835
R01 · FY2014 · CA · contact PI
Validation of Genomic Targets in Melanoma$305,300
R01 · FY2014 · CA · contact PI
Validation of Genomic Targets in Melanoma$323,587
R01 · FY2013 · CA · contact PI
Validation of Genomic Targets in Melanoma$351,145
R01 · FY2012 · CA · contact PI
Validation of Genomic Targets in Melanoma$370,543
R01 · FY2011 · CA · contact PI
Molecular Classification of Primary Cutaneous Melanoma$310,914
R01 · FY2011 · CA · contact PI
Molecular Classification of Primary Cutaneous Melanoma$320,530
R01 · FY2010 · CA · contact PI
Molecular Classification of Primary Cutaneous Melanoma$293,550
R01 · FY2009 · CA · contact PI
Validation of genomic targets in melanoma$172,590
R01 · FY2009 · CA · contact PI
Validation of genomic targets in melanoma$122,281
R01 · FY2009 · CA · contact PI
Molecular Classification of Primary Cutaneous Melanoma$293,313
R01 · FY2008 · CA · contact PI
Validation of genomic targets in melanoma$288,354
R01 · FY2008 · CA · contact PI
Molecular Classification of Primary Cutaneous Melanoma$292,363
R01 · FY2007 · CA · contact PI
Validation of genomic targets in melanoma$287,615
R01 · FY2007 · CA · contact PI
Validation of genomic targets in melanoma$293,015
R01 · FY2006 · CA · contact PI
Validation of genomic targets in melanoma$47,715
R01 · FY2006 · CA · contact PI
Validation of genomic targets in melanoma$297,317
R01 · FY2005 · CA
IMMUNOTHERAPY WITH A POLYVALENT MELANOMA VACCINE: POST SURGICAL TX FOR MELANOMA$91,192
M01 · FY2005 · RR
Non-viral Cutaneous Gene Delivery$75,750
R03 · FY2005 · AR
C-VAX+BCG VS PLACEBO, POST SURGICAL, STAGE III MELANOMA$45,362
M01 · FY2005 · RR
Non-viral Cutaneous Gene Delivery$75,750
R03 · FY2004 · AR
Immunotherapy with a Polyvalent Melanoma Vaccine: Post Surgical Tx for Melanoma$38,029
M01 · FY2004 · RR
C-VAX+BCG vs Placebo, Post Surgical, Stage III Melanoma$25,555
M01 · FY2004 · RR
Non-viral Cutaneous Gene Delivery$75,750
R03 · FY2003 · AR